Takeda Pharmaceutical (TAK) Inventory Average (2018 - 2026)

Takeda Pharmaceutical's Inventory Average history runs 9 years deep, the most recent figure standing at $9.0 billion for Q1 2026.

• On a quarterly basis, Inventory Average rose 11.57% year-over-year to $9.0 billion in Q1 2026; TTM through Mar 2026 was $9.0 billion, a 11.57% increase from a year earlier, with the FY2026 full-year figure at $8.6 billion, up 5.42% from the prior year.
• Inventory Average was little changed at $9.0 billion in Q1 2026 per TAK's latest filing, from $9.0 billion in the prior quarter.
• Across five years, Inventory Average topped out at $9.0 billion in Q1 2026 and bottomed at $6.7 billion in Q4 2022.
• The 5-year median for Inventory Average is $8.0 billion (2024), against an average of $7.9 billion.
• Across the five-year window, Inventory Average fell 5.52% in 2022 and gained 18.19% in 2023, its largest moves.
• Year by year, Inventory Average stood at $6.7 billion in 2022, then climbed by 18.19% to $8.0 billion in 2023, then grew by 2.33% to $8.1 billion in 2024, then advanced by 10.29% to $9.0 billion in 2025, then gained by 0.48% to $9.0 billion in 2026.
• Per Business Quant, the three latest TAK Inventory Average figures stand at $9.0 billion (Q1 2026), $9.0 billion (Q4 2025), and $8.7 billion (Q3 2025).